CLINICAL_TRIALS
trial_result
· 2024-01-18
Clinical Trial Update: Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease [Phase 1, Phase 2]
Summary
A phase 1/2 trial of AVR-RD-02 using a lentiviral vector in Gaucher disease has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AVROBIO | Conditions: Gaucher Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-01-18